BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31713264)

  • 41. Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma.
    Kruck S; Eyrich C; Scharpf M; Sievert KD; Fend F; Stenzl A; Bedke J
    Int J Mol Sci; 2013 May; 14(6):10944-57. PubMed ID: 23708097
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
    Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma.
    Yang L; Liu Y; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Ann Surg Oncol; 2016 Mar; 23(3):1044-52. PubMed ID: 26467457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.
    Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Long Q; Xu J; Guo J
    Oncotarget; 2016 Sep; 7(39):63661-63668. PubMed ID: 27564117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Golgi Alpha-Mannosidase II as a Novel Biomarker Predicts Prognosis in Clear Cell Renal Cell Carcinoma.
    Li C; Guo L; Chen F; Yu W; Rao T; Ruan Y
    Oncol Res Treat; 2020; 43(6):264-275. PubMed ID: 32403105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
    BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhancement of Siglec-8 expression predicts adverse prognosis in patients with clear cell renal cell carcinoma.
    Ou C; Liu L; Wang J; Dai S; Qu Y; Xiong Y; Xi W; Xu J; Guo J
    Urol Oncol; 2017 Oct; 35(10):607.e1-607.e8. PubMed ID: 28619634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma.
    Sun D; Lu J; Ding K; Bi D; Niu Z; Cao Q; Zhang J; Ding S
    Med Oncol; 2013 Mar; 30(1):476. PubMed ID: 23371254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
    Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
    Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.
    Shim M; Song C; Park S; Choi SK; Cho YM; Kim CS; Ahn H
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2213-20. PubMed ID: 26215891
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
    Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
    J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
    Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
    Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
    Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
    Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma.
    Oz Atalay F; Aytac Vuruskan B; Vuruskan H
    APMIS; 2016 Apr; 124(4):257-62. PubMed ID: 26750935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
    Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma.
    Yang L; Wu Q; Xu L; Zhang W; Zhu Y; Liu H; Xu J; Gu J
    BMC Cancer; 2015 Feb; 15():67. PubMed ID: 25886010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Orai1 Expression Is Closely Related with Favorable Prognostic Factors in Clear Cell Renal Cell Carcinoma.
    Lkhagvadorj S; Kim JH; Oh SS; Lee MR; Jung JH; Chung HC; Cha SK; Eom M
    J Korean Med Sci; 2016 Jun; 31(6):879-85. PubMed ID: 27247496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.
    Li P; Liu J; Li J; Liu P
    Mol Biol Rep; 2019 Aug; 46(4):4377-4383. PubMed ID: 31147860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
    Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
    Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.